Stopping Pharma’s Ripoffs and Drug Savings For All Act

This bill targets pharmaceutical companies that extend patent protection for the same drug through multiple overlapping patents, a practice sometimes called "evergreening." It creates a presumption that companies must disclaim patent term for subsequent patents covering the same drug after the first patent expires, unless they prove the patents cover truly distinct inventions. The bill also requires the U.S. Patent Office to review its processes to prevent issuing such overlapping patents and report findings within a year. This directly affects pharmaceutical companies holding multiple patents for single drugs and aims to reduce artificial extensions of drug exclusivity, potentially lowering costs for consumers and insurers.